Recent advances in our understanding of HIV infection in patients with the acquired immunodeficiency syndrome (AIDS) are leading us to explore new treatment stragegies, including the use of combination antiretroviral therapy. In this review, we present information from recently completed clinical trials explore the use of combination therapy, including ACTG 175, the Delta studies, and the NUCA studies. In addition, we present preliminary about use of protease inhibitors, the newest class of antiretrovirals.

Results of recent investigations have given us a new understanding of the pathogenesis of HIV infection. This findings provide us with a kinetic model of pathogenesis in which continuous, high-grade viral replication. This findings provide us with a kinetic model of pathogenesis in which continuous, high-grade viral replication is the principal force driving the destruction of CD4 lymphocytes. This knowledge will lead us to design better treatment strategies directed to curtail viral replication and prevent the emergence of viral resistance, and the use of combination antiretroviral therapy is a first example of these new strategies. The concept of viral load is introduced, and we discuss the usefulness of viral load in the clinical prognosis of this disease, and its use as an aid in the decision-making process when starling or mordifyng antiretroviral therapy in our patients.

Introduction: anemia is a common and serious complication of both HIV infection and its treatment. Severe anemia is a life-threatening condition and its causes in these patients are multiple but their frequency is unknown. Objective: of the study was to evaluate the causes of severe anemia in HIV infected adults at the time of admission to Jackson Memorial Hospital (JMH) in Miami. Materials and Methods: we reviewed the cases of severe anemia (hematocrit < 20% on admission) in HIV seropositive adults admitted to JMH between 5/96 to 5/97. Results: there were 53 patients, (27 men, 26 women). The mean CD4 cell count was 47cells/mm3 and 67% of the patients had a CD4 cell count less than 50 cells/mm3. Sixty-four percent of the patients were on antiretroviral therapy, including AZT (94%) and protease inhibitors (29%). The mean hematocrit on admission was 16% and the mean number of units of b...

Introduction: anemia is a common and serious complication of both HIV infection and its treatment. Severe anemia is a life-threatening condition and its causes in these patients are multiple but their frequency is unknown. Objective: of the study was to evaluate the causes of severe anemia in HIV infected adults at the time of admission to Jackson Memorial Hospital (JMH) in Miami. Materials and Methods: we reviewed the cases of severe anemia (hematocrit < 20% on admission) in HIV seropositive adults admitted to JMH between 5/96 to 5/97. Results: there were 53 patients, (27 men, 26 women). The mean CD4 cell count was 47cells/mm3 and 67% of the patients had a CD4 cell count less than 50 cells/mm3. Sixty-four percent of the patients were on antiretroviral therapy, including AZT (94%) and protease inhibitors (29%). The mean hematocrit on admission was 16% and the mean number of units of b...

Large, ulcerative lesions over the skin scalp, and oral mucosa were observed in a patient with acquired immunodeficiency syndrome (AIDS) receiving chronic suppressive therapy with fluconazole. Candida glabrata was recovered in culture from biopsy material, and was found to be resistant to reported frequency of infections with Candida spp. resistant to fluconazole has increased in recent years. We review the literature regardin fluconazole resistant infections in patients with AIDS, discuss the possible mechanisms of resistance, and management options.

Objetivo: Evaluar la eficacia del danazol para el tratamiento de la trombocitopenia asociada con el virus de la inmunodeficiencia humana tipo 1 (HIV-1). Pacientes y Métodos: Estudio retrospectivo, diseño serie de casos. Se identificaron 8 pacientes con trombocitopenia asociada a infección con HIV-1 que fueron tratados con danazol (300-800 mg/día) por más de 3 meses. El seguimiento fue de 3 meses a 2 años. Se definió respuesta favorable al tratamiento como un incremento en el recuento de plaquetas por encima del 25% con referencia a los valores pre-tratamiento. Resultados: El recuento de plaquetas promedio (± desviación estándar) antes de la terapia con danazol fue de 51±24 x 109/L, con un rango de 19-88 x 109/L. Siete (87%) de los 8 pacientes tuvieron respuestas favorables al danazol. Los recuentos promedio a 12 y 24 meses de terapia fueron 104± 108 x 109/L, y 112± 2...